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Objectives. To report on a novel IIF pattern specifically associated with antibodies to DNA topo I.
Methods. A novel compound IF pattern, designated Scl-70 pattern, was characterized in routine ANA-HEp-2 IIF screening. Within the last
3 years, all serum samples presenting the Scl-70 pattern at the ANA-HEp2 IIF screening were tested for anti-topo I reactivity. Conversely,
16 serum samples with known anti-topo I reactivity and affinity-purified anti-topo I antibody preparations were tested for the Scl-70 pattern.
Results. The Scl-70 pattern comprised the staining of five cellular regions: nucleus, nucleolus and cytoplasm in interphase cells; nucleolar
organizing region (NOR) and chromosomes in mitotic cells. All 81 serum samples selected as Scl-70 pattern reacted with topo I. All 16 anti-
topo I samples and antibody preparations reproduced the Scl-70 pattern. This compound IF pattern was consistently observed in different
commercial HEp-2 cell slides and in home-made slides with HEp-2 cells and human fibroblasts fixed with alternative protocols. Double IIF
experiments demonstrated the co-localization of topo I and human upstream binding factor at the NOR.
Conclusions. The Scl-70 pattern belongs to the group of compound IF patterns that hold strong association with the respective autoantibody
specificities, such as that observed with centromere protein F (CENP-F) and nuclear mitotic apparatus-1 (NuMA-1) protein. The identification
of the Scl-70 pattern at routine ANA-HEp-2 IIF screening may lead to implementation of specific tests for the identification of anti-topo
I antibodies. In addition, the Scl-70 pattern outlines cellular domains other than those previously reported for topo I, which is of interest
for further understanding the roles of this enzyme in cell biology.
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Introduction
The standard method of screening for ANAs has been the IIF
assay on HEp-2 cells (ANA-HEp-2 IIF) [1]. In addition to its
usefulness as a screening tool, the ANA-HEp-2 IIF assay is also
able to provide hints for the autoantibody specificity in a given
sample. HEp-2 cell line (American Type Culture Collection
CCL23, Rockville, MD, USA) is derived from human epithelial
carcinoma and grows in monolayers of widely spread cells that
nicely display a well-organized array of cell domains. Each cell
domain is enriched with a distinct set of antigens. Therefore, the
IF pattern depicted with a given serum is a function of the topo-
graphic distribution of the antigens recognized by the antibodies
present in that serum. In fact, it has been broadly recognized that
some IF patterns are associated with certain autoantibodies. For
example, the nuclear coarse speckled pattern is strongly associated
with anti-Smith (anti-Sm) and anti-snRNP antibodies [2, 3], and
the nuclear homogeneous pattern is associated with antibodies to
native DNA, nucleosome and histones [4].
Since cell domains contain several molecular components that
may be target of autoantibodies, a given IF pattern is usually
associated with more than one autoantibody specificity. For
example, the IF pattern associated with the Golgi complex may
be elicited by autoantibodies to several of the Golgi constituents,
such as giantin/macrogolgin/GCP372, golgin-245/p230, GMAP-
210, golgin-160/GCP170, golgin-95/GM130 and golgin-97
[5–10]. The IF pattern associated with the nucleolus may be
elicited by autoantibodies to several nucleolar constituents, such
as Th/To, fibrillarin, NOR90 (nucleolar organizing region-90),
RNA polymerase I and nucleolin, involved in various stages of
ribosomal biosynthesis and processing [11–13]. Therefore, the
ANA-HEp-2 IF pattern may provide hints on the autoantibody
specificity, but in general additional tests are required for the
definite autoantibody identification.
However, there are some exceptions in which the IF pattern is
strongly associated with a given autoantibody specificity. In fact,
some autoantigens are expressed in more than one cell domain
and some of these may undergo repositioning along the cell
cycle. The resulting compound topographic distribution may be
such that it is not shared by other autoantigens located in any of
the isolated cellular domains that make up the compound pattern.
Compound IF patterns may present such a strong association
with the target autoantigens that they may be interpreted as
virtually specific for the respective autoantibodies. One example
is the characteristic pattern displayed by antibodies to nuclear
mitotic apparatus (NuMA-1) protein, which is represented by a
compact fine speckled staining of the nucleus of interphase cells
and a peculiar staining of the mitotic poles and spindle fibres in
metaphase cells [14]. Samples staining the mitotic poles without
the concomitant fine speckled staining of interphase nucleus are
not associated with NuMA-1 antibodies and none of the samples
with anti-NuMA-1 antibodies failed to present the characteristic
NuMA-1 compound IF pattern. Another example is the
compound pattern associated with anti-centromere protein F
(anti-CENP-F) antibodies [15]. This highly pleomorphic pattern
is characterized by heterogeneous fine speckled staining of the
interphase nucleus, centromeric staining restricted to mitotic
cells and a characteristic staining of the mid-body and intercellular
bridge. Virtually all samples presenting this specific pattern
are reactive to CENP-F [15].
Autoantibodies reacting with DNA topo I are serological
markers of SSc. They are observed in up to 30% of the unselected
SSc patients and are associated with diffuse skin involvement and
more aggressive forms of the disease [16]. Anti-DNA topo I
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on HEp-2 cells characterized by nuclear and nucleolar fine
speckled staining of interphase cells. In addition, mitotic cells
display a fine speckled staining of the metaphase plate [17, 18].
Although usually observed with sera containing anti-DNA topo I
antibodies, this pattern is not considered specific for these
autoantibodies. In our routine ANA-HEp-2 IIF analysis, we
have observed additional features in the IF pattern associated
with anti-DNA topo I antibodies. This compound IF pattern,
herein designated as Scl-70 pattern [original designation for the
autoantigen (DNA topo I) recognized by some SSc sera],
comprises the staining of five cellular domains along the cell
cycle. The objective of this report is to characterize the compound
Scl-70 pattern and to demonstrate its strong association with
anti-DNA topo I antibodies.
Materials and methods
Within the last 3 years, all serum samples presenting the Scl-70
pattern (see Results section for details) at the routine ANA–
HEp2 screening were investigated for the presence of anti-DNA
topo I antibodies. These comprised a total of 81 Scl-70 pattern
samples. In addition, serum samples with known reactivity to
DNA topo I and purified anti-DNA topo I antibody preparations
were tested in the ANA-HEp-2 IIF assay for the presence of the
Scl-70 pattern. These comprised 16 samples of patients with SSc
defined according to the standard criteria [19], the centers for
disease control (CDC) reference human anti-DNA topo I serum
(No. IS—2135 lot No. 84-0027, ANA Reference Human Serum
No. 9 pos. anti-Scl 70), commercial positive anti-DNA topo I
standard control (Bio-Rad Laboratories, Hercules, CA, USA),
FIG. 1. The compound IF pattern Scl-70 comprises the staining of five cell domains: nucleus (1), nucleolus (2), cytoplasm (3) in interphase cells, NOR (4) and chromosome
metaphase plate (5) in mitotic cells. The boxes in white outline blow-up details of the delicate cytoplasm staining. The interphase nucleus is stained as a strong compact fine
speckled pattern; the nucleolus is weakly and variably stained; the cytoplasm depicts a weakly stained dot/reticular network from the perinuclear area to the plasma
membrane; in mitotic cells the chromosome mass is strongly stained similarly to the interphase nucleus and there is an enhanced staining at discrete spots at the
metaphase plate, resembling the NOR domains (inset). IIF on HEp-2 cells (Bion, Des Plaines, IL, USA) with human monospecific anti-Scl-70 serum diluted 1:80. Scale
bars¼5mm.
Specific anti-Scl-70 IF pattern 633Sepharose affinity-purified anti-DNA topo I antibody pre-
paration (kindly donated by Dr R. W. Burlingame, Inova
Diagnostics, San Diego, CA, USA) and western blot-based affi-
nity-purified anti-DNA topo I antibody preparation. Affinity
purification of anti-DNA topo I antibodies from SDS–PAGE
nitrocellulose membranes was performed as previously described
[20] using a high titre SSc serum sample with anti-DNA topo I
reactivity determined by double ID and western blot. Informed
consent was obtained from patients with SSc, who donated serum
samples for the experiments. The study was approved by the ethics
committee at Fleury Research and Development Institute.
IIF was performed at the dilution of 1:80 according to the
standard protocol [1] on a variety of cell substrates, including
commercial HEp-2 cell slides from six different suppliers
[Hemagen Diagnostics, Bion Enterprise, Bio-Rad Laboratories
(Columbia, MD, USA), Inova Diagnostics, The Binding Site
(Birmingham, UK) and IMMCO Diagnostics (Buffalo, NY,
USA)], home-made HEp-2 cell slides and home-made human
dermal fibroblasts slides. For the home-made slides, HEp-2 cells
(ATCC, American Type Culture Collection CCL23) were grown
to subconfluency and transferred to appropriate 12-well glass
slides. After an additional 24-h period at DMEM (Gibco
Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum (Gibco Invitrogen Life Technologies) at
5% CO2 and 378C, cells were fixed in methanol at  208C for
5min and acetone at  208C for 2min. Alternatively, cells were
fixed in 4% paraformaldehyde for 30min at room temperature,
washed three times in 0.15M phosphate buffered saline (PBS) of
pH 7.2, incubated in 50mM ammonium chloride for 15min, per-
meabilized in acetone at  208C for 2min and kept in PBS at 48C
until use. Primary human fibroblast culture was obtained by
explant from forearm biopsy of normal volunteers and grown
on round glass cover slips to subconfluency. Fixation in parafor-
maldehyde was performed as above. All slides were analysed by
three independent observers in an Olympus (Center Valley, PA,
USA) B 50 fluorescence microscope at  400 magnification.
Images captured with a QColor 3 camera (Olympus) were ana-
lysed with the Image-J and Image-Pro Plus 5.1 software (Media
Cybernetics, Bethesda, MD, USA).
For double IIF, commercial HEp-2 slides were incubated
with anti-human upstream binding factor (anti-hUBF) murine
monoclonal IgG (F-9 Sc-13125, lot L1703, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) in the ratio 1:100 for 1h
at 378C, washed in PBS and incubated with different anti-DNA
topo I human serum samples diluted 1:80 for 1h at 378C.
Alternatively, cells were incubated with affinity-purified anti-
DNA topo I antibody preparations diluted 1:5 (western blot pur-
ification) and 1:100 (protein A–Sepharose purification) in PBS.
After a further washing step as before, cells were incubated with
anti-murine IgG (Alexa Fluor 568 mouse, A11031 L84E2-1,
Invitrogen, Molecular Probes) and anti-human IgG in 1:100
ratio (FITC, Bion Enterprise, Des Plaines, IL, USA, CCP-0269)
FIG. 2. Complete co-localization of the domains stained by human anti-DNA topo I serum and NORs in cells at metaphase (A), anaphase (B) and telophase (C). From
the left to the right, pictures depict the staining obtained with DAPI, human anti-Scl-70 serum/FITC conjugate, mouse anti-UBF monoclonal antibody/Alexa Fluor 568
conjugate and merging of the latter two images, respectively. Single optical sections acquired by confocal microscopy of IIF on HEp-2 cells (Bion, Park Ridge, IL, USA) with
human monospecific anti-Scl-70 serum diluted to 1:80 ratio, mouse monoclonal anti-UBF antibody in the ratio 1: 100 and DAPI II (125ng/ml Abbott Molecular, Des Plaines,
IL, USA, 30-804931). Magnification bars¼5 and 10mm.
634 Alessandra Dellavance et al.for 1h at 378C. After a final washing step, slides were mounted
with buffered glycerin and 40,6-diamidino-2-phenylindole
dihydrochloride II (DAPI II) (125ng/ml, Abbott Molecular,
# 30-804931) and analysed in a scanning confocal fluorescence
system (Bio-Rad Laboratories MRC1024 UV) attached to a
Zeiss Axiovert 100 microscope, using either a 40  1.2NA water
immersion or a 100  1.4 oil immersion PlanApochromatic
objective.
Antibodies to DNA topo I were determined by standard double
ID assay and western blot. The ID assay was performed as
previously reported [21] with rabbit thymus extract (Pel Freez
Biologicals, Rogers, AR, USA) and secondary standard anti-
DNA topo I serum previously established from the sample
provided by the Centers for Disease Control (No. IS-2135 lot
No. 84-0027; CDC, Atlanta, GA, USA). Western blot was per-
formed with HEp-2 whole cell extract separated in 10% SDS–
PAGE according to the previously established method [22].
Briefly, serum samples were tested at 1:50 dilution in 5% skim
milk 0.05% Tween-20 in PBS (MT-PBS) for 1h at room tempera-
ture under shaking. Alternatively, strips were incubated with wes-
tern blot-based affinity-purified anti-DNA topo I antibody
preparation diluted to the ratio 1:5 in MT-PBS. After two 15-
min washing steps in 0.05% Tween–PBS, nitrocellulose strips were
incubated with horseradish peroxidase-labelled anti-human IgG
(Bio-Rad Laboratories) diluted to the ratio 1:1500 in MT-PBS
for 1h at room temperature in the dark under shaking. After
washing with 0.05% Tween–PBS for 15min and with PBS for
15min, strips were incubated with chromogenic solution
(6mg 4-chloro-1-naphthol in 2ml methanol, 10ml PBS and
20ml 30% H2O2). The reaction was stopped with water.
Results
Definition of the Scl-70 IF pattern
The IF pattern designated Scl-70 pattern comprises the staining of
five cell domains: nucleus, nucleolus, cytoplasm in interphase cells,
NOR and chromosome metaphase plate in mitotic cells (Fig. 1).
The interphase nucleus is stained as a compact fine speckled pat-
tern and there is a faint and inconsistent enhancement of the
staining at the nucleolus. The cytoplasm depicts a weakly stained
network from the perinuclear area towards the plasma membrane.
The chromosome mass in mitotic cells is consistently stained.
In addition, there is an enhanced staining at discrete spots at
the metaphase plate, resembling the NOR domains (Fig. 1).
This compound IF pattern was consistently observed in all
commercial HEp-2 cell slides, in home-made HEp-2 cells fixed
with the methanol/acetone and with the paraformaldehyde
protocols and in human fibroblasts (data not shown). Double
IIF experiments analysed by confocal microscopy demonstrated
co-localization of DNA topo I reactivity and human upstream
binding factor at the NOR at metaphase, anaphase and telophase
(Fig. 2).
Association of the Scl-70 IF pattern and anti-DNA topo I
antibodies
All the 81 serum samples selected in the routine ANA-HEp-2
screening due to the presence of the Scl-70 pattern were confirmed
to present anti-DNA topo I antibodies by double ID and by
western blot (Fig. 3). Of interest, none of the samples presented
the 88–90kDa doublet characteristic of anti-NOR-90 antibodies.
Four samples had the precipitation line on the ID assay formed
only after 72h on diffusion but had indistinguishable character-
istics at the ANA-HEp-2 IIF and western blot assays. Conversely,
the Scl-70 IF pattern was consistently observed in all 16 SSc serum
samples with confirmed anti-DNA topo I antibodies. In addition,
the ANA-HEp-2 Scl-70 pattern was also observed with the CDC
reference human anti-DNA topo I serum, with the commercial
anti-DNA topo I standard serum and with the affinity-purified
anti-DNA topo I antibody preparations (Fig. 4). As a control,
affinity-purified antibodies from irrelevant areas of the western
blot membrane yielded no relevant staining in the HEp-2 IIF
assay (data not shown).
Discussion
In the present study, we originally demonstrated that anti-DNA
topo I antibodies present a compound IF pattern encompassing
the nucleus, nucleolus, NOR, metaphase chromosome plate and
the cytoplasm. This compound pattern was consistently observed
in different cellular substrates and with different fixation proto-
cols. The Scl-70 pattern proved to be specific for anti-DNA topo I
antibodies, since 81 sequentially selected Scl-70-pattern serum
samples were shown to be reactive with DNA topo I in double
ID and western blot. In addition, all tested SSc serum samples
with known reactivity to DNA topo I presented the ANA-HEp-2
Scl-70 pattern. Finally, affinity-purified anti-DNA topo I
antibody preparations could reproduce the Scl-70 pattern.
The recognition of such specific compound IF pattern
has important implications from the clinical point of view. The
Scl-70 pattern herein characterized belongs to the group of
compound IF patterns that hold strong autoantibody specificity
association, such as those observed with CENP-F and NuMA-1
autoantibodies [14, 15]. The identification of such specific com-
pound patterns in a given sample at the routine ANA-HEp-2
IIF screening leads to the implementation of specific tests
for the definitive identification of the respective autoantibody.
The HEp-2 cell IF pattern traditionally associated with anti-
DNA topo I antibodies refers solely to a fine speckled staining
of the nucleus, nucleolus and metaphase plate, which is not exclu-
sively associated with this autoantibody specificity. The Scl-70
pattern herein reported has two additional features (the cytoplasm
dot/reticular in interphase cells and the NOR at mitotic cells)
that contribute to its specific association with anti-DNA topo I
antibodies. The cytoplasmic component of the Scl-70 pattern has
FIG. 3. Western blot with whole HEp-2 cell extract separated in 10% SDS–
PAGE and probed with sera diluted in the ratio 1:50. Lane 1: western blot-based
affinity-purified antibodies reacting with DNA topo I; lanes 2–4: representative sera
depicting the Scl-70 pattern on IIF in HEp-2 cells; lane 5: negative control. Arrow
indicates proteins migrating with mobility compatible with 100kDa.
Specific anti-Scl-70 IF pattern 635never been previously reported and the presence of DNA topo I at
the NOR has been previously reported in PtK2 cells but not
in HEp-2 cells [23].
The characterization of the compound Scl-70 pattern is also
relevant to further understanding of the cell biology of DNA
topo I since it indicates the putative cellular domains where the
enzyme activity might be involved. DNA topoisomerases are
required for relaxation of the DNA helix as it uncoils for DNA
replication and RNA transcription. The relaxation process is
obtained through DNA cleavage in which a transient phosphodies-
ter bond is formed between a tyrosine residue in the protein and
one of the ends of the broken strand. DNA conformation can thus
be modified as long as the covalent intermediate persists, and the
enzyme is released as the ruptured DNA strand is re-connected.
Type I topoisomerases cleave only one DNA strand and type II
topoisomerases cleave both DNA strands [24]. Human topo I is
a 91kDa protein of 765 amino acids localized to the nucleus
due to the existence of a functional nuclear localization signal
[nuclear localization signal (NLS-II), amino acids 150–6] at the
N-terminal domain. In addition, there is a second nuclear loca-
lization signal (NLS-IV, amino acids 157–99) that is important
for nucleolar localization [25].
Chromosome condensation during mitosis involves the genera-
tion of right-handed solenoidal supercoils and this implies that
topo I would be required at this stage of the cell cycle to relax
compensatory negative supercoils [26]. Double mutant yeasts
lacking the trf4 and top1 genes are defective in establishing chro-
mosome condensation, spindle elongation and nuclear segregation
[27]. These observations may justify the persistence of topo I
attached to chromatin during mitosis rendering the characteristic
fine speckled staining of the metaphase plate. The enhancement of
topo I staining at the NOR in human HEp-2 cell line expands
previous similar finding in rat kangaroo PtK2 cells [23]. This
morphological finding is supported by previous demonstration
of strong binding of DNA topo I to ribosomal DNA (rDNA)
in virus-transformed chicken MSB-1T-cell line [28]. The associa-
tion of DNA topo I to rDNA may be related to two factors.
First, there is some evidence that topo I plays an important role
in maintaining the integrity of the rDNA locus [29]. Secondly,
RNA polymerases are extremely powerful motors that can prob-
ably overcome substantial frictional resistance while translocat-
ing along its DNA template in the absence of DNA
topoisomerase activity [30]. The cluster organization of rDNA
genes might contribute to a paramount DNA helix tension at
the rDNA gene loci. Therefore, the enrichment of topo I at the
NOR in mitotic cells appears to be appropriate to match the
requirement for immediate rRNA transcription right after
mitosis [31].
FIG. 4. The compound IF Scl-70 pattern is reproduced by affinity-purified antibodies to DNA topo I. IIF on HEp-2 cells (Bion) with human monospecific anti-DNA topo I
serum diluted to the ratio 1:80 (A), western blot-based affinity-purified anti-DNA topo I antibody preparation diluted 1:5 (B and inset) and protein A–Sepharose-based
affinity-purified anti-DNA topo I antibody preparation diluted 1:100 (C). Scale bars ¼7.5mm.
636 Alessandra Dellavance et al.The cytoplasmic component of the Scl-70 pattern has never
been reported previously. In fact, such a finding is surprising
since DNA topo I is not expected to play any role at cytoplasmic
domains. The considerably weaker intensity of the cytoplasmic
staining in comparison with the nuclear staining suggests that
the observed staining might be due to cross-reactivity of anti-
DNA topo I autoantobodies with some cytoplasmic protein.
In fact, mitochondria have a specific topoisomerase species [32],
and we speculate that this protein might be recognized by anti-
DNA topo I autoantibodies. The human mitochondrial topo I
gene (TOP1mt) is located at 8q24.3 and consists of 14 exons.
The last 13 exons have the exact same size and intron frame as
the nuclear topo I gene. The high degree of homology between
TOP1mt and nuclear top1 is striking at the amino acid and
nucleotide levels. In contrast to the nuclear topo I, mitochondrial
topo I lacks an amino acid sequence corresponding to a nuclear
localization signal. Its N-terminal sequence has positively charged
residues that could fold in a positively charged amphiphilic helix
suggestive of a mitochondrial targeting signal. Due to the high
amino acid homology of nuclear and mitochondrial topoisome-
rase species, it is conceivable that the weak dot/reticular cytoplas-
mic staining observed in the Scl-70 pattern is due to cross-
reactivity. This point is currently under investigation in our
laboratory.
In conclusion, we have originally reported on a novel com-
pound ANA-HEp-2 IF pattern, the Scl-70 pattern, which is
specifically associated with anti-DNA topo I autoantibodies.
The recognition of the Scl-70 pattern may be useful in providing
relevant information in ANA-HEp-2 IIF screening in the clinical
laboratory setting and may contribute to further elucidating the
role of this important nuclear enzyme in cell biology.
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Rheumatology key messages
  Autoantibodies to DNA topo I yield a specific IF pattern on
ANA-HEp-2 IIF test.
  The finding of the Scl-70 pattern on the ANA screening may lead
to routine determination of anti-DNA topoisomerase antibody.
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